Related Experiment Video

Updated: Oct 12, 2025

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

2.6K

RAC1 Activation as a Potential Therapeutic Option in Metastatic Cutaneous Melanoma

Paula Colón-Bolea1, Rocío García-Gómez1,2, Berta Casar1,2

  • 1Instituto de Biomedicina y Biotecnología de Cantabria, Consejo Superior de Investigaciones Científicas-Universidad de Cantabria, 39011 Santander, Spain.

Biomolecules
|November 27, 2021
PubMed

Insights

Targeting RAC1, a key protein in cancer spread, shows promise for treating metastatic cutaneous melanoma. Drugs targeting RAC1 may inhibit cancer cell migration and invasion, offering new therapeutic strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Metastasis is a critical process in cancer progression, involving cancer cell escape and colonization of distant organs.
  • RAC1, a RHO family GTPase, is crucial for cancer cell migration, invasion, angiogenesis, and metastasis.
  • RAC1 alterations, including mutations and overexpression, are implicated in various cancers like melanoma, breast, lung, and pancreatic cancer.

Purpose of the Study:

  • To review the role of RAC1 in metastatic cutaneous melanoma.
  • To highlight the anti-metastatic potential of RAC1-targeting drugs in melanoma treatment.

Main Methods:

  • Literature review focusing on RAC1's role in cancer metastasis.
  • Analysis of studies investigating RAC1 alterations and targeted therapies in cutaneous melanoma.

Main Results:

  • RAC1 activation is linked to increased migration, invasion, and angiogenesis in cancers.
  • The RAC1P29S mutation is prevalent in cutaneous melanoma cases.
  • RAC1 hyperactivation through oncogenic receptors contributes to therapeutic resistance.

Conclusions:

  • Targeting RAC1 is a promising therapeutic strategy for cutaneous melanoma.
  • Inhibiting RAC1 may counteract metastatic processes and overcome resistance to targeted therapies.
Keywords:
RAC1cutaneous melanomainvasionmetastasistherapy resistance

More Related Videos

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

9.0K
A 3D Organotypic Melanoma Spheroid Skin Model08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

16.0K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.7K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
6.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.2K